Pancreatic Cancer

Pancreatic Cancer in 2026: Where Things Stand

June 2026 · Camilo Correa, MD

Pancreatic cancer remains one of the most difficult cancers to treat. Most pancreatic cancers are pancreatic ductal adenocarcinomas, the type people usually mean when they say “pancreatic cancer.” It is often found late, it can spread early, and it does not always respond well to treatment. That reality has not changed.

What has changed is how we evaluate and treat it.

We are getting better at choosing the right treatment sequence

Years ago, treatment decisions were often based mostly on whether the tumor looked removable on a CT scan. That is still important, but it is no longer the whole picture.

Today, a good treatment plan should consider:

• Where the tumor is located
• Whether it involves nearby blood vessels
• Whether there is any spread outside the pancreas
• The patient’s strength, nutrition, and overall health
• Blood tests such as CA 19-9
• Genetic and molecular testing
• The opinion of a multidisciplinary team

That team usually includes surgery, medical oncology, radiation oncology, radiology, pathology, genetics, nutrition, and supportive care.

For some patients, surgery is the first step. For others, chemotherapy is given first to treat cancer cells that may already be outside the pancreas, even if they cannot yet be seen on scans. In selected patients, chemotherapy can also make surgery safer or more effective later.

Surgery still matters, but it has to be used carefully

Surgery remains the only treatment that can cure pancreatic cancer. But surgery alone is rarely enough.

Even after a successful operation, recurrence is common. This is why chemotherapy before or after surgery is so important. The operation removes the visible cancer. Chemotherapy treats disease that may be too small to detect.

For tumors in the head of the pancreas, the usual operation is a Whipple procedure. For tumors in the body or tail, the usual operation is a distal pancreatectomy, often with removal of the spleen. In some cases, surgery may involve nearby veins or arteries, which should be handled by teams with deep pancreatic surgery experience.

Minimally invasive and robotic surgery can help some patients recover faster, especially for tumors in the body or tail of the pancreas. But the priority is not the size of the incision. The priority is safe surgery, complete cancer removal when possible, and a plan that fits the biology of the disease.

Chemotherapy has improved

Modern chemotherapy has improved outcomes compared with older treatments. Common regimens include FOLFIRINOX, modified FOLFIRINOX, gemcitabine with nab-paclitaxel, and newer combinations such as NALIRIFOX.

These treatments are not easy. They can cause fatigue, nausea, low blood counts, diarrhea, nerve symptoms, appetite loss, and weight loss. But for many patients, they can slow the cancer, shrink tumors, help patients reach surgery, or extend life.

Choosing the right chemotherapy depends on the patient’s fitness, age, other medical problems, goals, and likely side effects. More treatment is not always better. Better-selected treatment is usually the goal.

Genetic and molecular testing is now essential

Every patient with pancreatic cancer should ask whether genetic testing and tumor testing are appropriate. These tests can identify changes that may affect treatment.

Examples include:

• BRCA1, BRCA2, PALB2, and other DNA repair genes
• MSI-high or mismatch repair deficiency, which may make immunotherapy useful in a small group of patients
• NTRK or NRG1 fusions, which are rare but may be treatable
• KRAS mutations, which are very common in pancreatic cancer and are now a major focus of drug development

Most patients will not have an immediately targetable result. Still, testing matters because the small group who do may benefit from a more personalized treatment. Results may also affect family members, especially if an inherited mutation is found.

KRAS-targeted drugs are one of the most important areas of research

Most pancreatic cancers have a change in a gene called KRAS. For decades, KRAS was considered extremely difficult to target with drugs. That is changing.

Early studies of KRAS-directed and broader RAS-directed drugs are encouraging, especially because KRAS changes are so common in pancreatic cancer. These treatments are still being studied, and they are not yet a routine answer for most patients. But they are among the most important developments in the field.

Patients with advanced pancreatic cancer should ask whether clinical trials are available, especially trials involving molecular testing, KRAS-directed therapy, vaccine therapy, or new combinations of chemotherapy and targeted drugs.

Immunotherapy helps only a small group so far

Immunotherapy has changed treatment for several cancers, but pancreatic cancer has been much harder. Standard immunotherapy drugs usually do not work well for most patients with pancreatic cancer.

There are exceptions. Patients whose tumors are MSI-high or mismatch repair deficient may respond well to immunotherapy, but this represents only a small percentage of pancreatic cancers.

Vaccine-based treatments, including personalized RNA vaccines, are also being studied after surgery. Early results are promising, but these approaches remain investigational.

Earlier detection is still the biggest unmet need

Pancreatic cancer is often diagnosed after it has already spread or grown into nearby structures. This is one of the main reasons outcomes remain poor.

Routine screening is not recommended for the general population because current tests are not accurate enough for everyone. Screening is different for people at higher risk, such as those with strong family history or certain inherited mutations. These patients may benefit from surveillance with MRI and/or endoscopic ultrasound in specialized programs.

New-onset diabetes after age 50, unexplained weight loss, jaundice, persistent upper abdominal or back pain, and new digestive problems can sometimes be warning signs. Most people with these symptoms do not have pancreatic cancer, but persistent or unexplained symptoms deserve medical evaluation.

Supportive care is part of cancer care

Good pancreatic cancer care is not only chemotherapy and surgery. Patients often need help with nutrition, digestion, pain, diabetes, fatigue, and emotional distress.

Many patients benefit from pancreatic enzyme replacement, especially if they have weight loss, bloating, oily stools, diarrhea, or difficulty maintaining nutrition. Palliative care can also be helpful early in treatment. Palliative care is not the same as hospice. It focuses on symptom control, quality of life, and helping patients tolerate treatment.

The practical message

Pancreatic cancer remains serious, but care is becoming more precise. The best outcomes usually come from early multidisciplinary evaluation, careful staging, genetic and molecular testing, attention to nutrition and symptoms, and access to clinical trials when appropriate.

For patients and families, the most useful questions are often:

• Has my case been reviewed by a multidisciplinary pancreatic cancer team?
• Is surgery possible now, later, or not safely?
• Should chemotherapy come before surgery?
• Have I had genetic testing?
• Has my tumor had molecular testing?
• Are there clinical trials that fit my situation?
• Do I need pancreatic enzymes, nutrition support, pain management, or palliative care?

Pancreatic cancer treatment is moving forward, but it still requires careful decision-making. The goal is not just to do more. The goal is to choose the right treatment, at the right time, for the right patient.

This article is for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with your care team based on your individual situation.

← Back to Patient Education & News